Pembrolizumab-induced diabetes

Endokrynol Pol. 2021;72(4):414-415. doi: 10.5603/EP.a2021.0053. Epub 2021 May 31.

Authors

Rumaisa Banatwalla¹, Omar Zuhair Kirresh², Fahad Wali Ahmed³

Affiliations

¹ Specialist Registrar in Endocrinology and Diabetes, King's College Hospital NHS Foundation Trust, London, United Kingdom.
² Consultant in Diabetes and Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
³ Consultant in Diabetes and Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom. fahadwali@yahoo.com.

PMID: 34057191
DOI: 10.5603/EP.a2021.0053

Abstract

Not required for Clinical Vignette.

Keywords: check-point inhibitors; diabetes; diabetic ketoacidosis; malignant melanoma; pembrolizumab.

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Diabetes Mellitus, Type 1*
Humans

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab